Researchers at Oregon Health & Science University have developed a blood test capable of detecting signals for more than 50 types of cancer [1].
This development is significant because many cancers, particularly pancreatic cancer, are often diagnosed too late for effective treatment. By identifying these signals before symptoms appear, the test could allow for earlier medical intervention and improved patient survival rates [2], [4].
Dr. Darien Sutton, an ABC News medical correspondent, said the tool is a potential breakthrough in oncology [1]. The test focuses on identifying biomarkers in the blood that indicate the presence of malignant cells. This approach allows clinicians to screen for a wide array of malignancies through a single sample [1], [3].
The research originates from Portland, Oregon, where scientists are refining the test's ability to spot early-stage indicators [5]. Early detection is critical for deadly cancers that do not present obvious symptoms in their initial phases [3], [5].
While the test targets over 50 different cancers [1], the researchers are specifically emphasizing its utility in spotting pancreatic cancer early. This specific cancer is known for its high mortality rate due to late-stage discovery [5].
The team aims to transition this tool into broader clinical use to change how the medical community approaches cancer screening. Rather than relying on symptom-based diagnosis, the test provides a proactive method for identifying disease [2], [4].
“The test can detect signals for more than 50 types of cancer.”
The shift toward multi-cancer early detection (MCED) tests represents a move toward proactive rather than reactive oncology. If validated for widespread clinical use, this technology could reduce the reliance on invasive biopsies for initial screening and significantly increase the percentage of cancers caught in treatable stages, particularly for high-mortality organs like the pancreas.
